For the quarter ending 2025-09-30, HEPA had -$603,317 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Effect of exchange rates on cash | 0 | 0 |
| Depreciation | 0 | 0 |
| Amortization of debt discount | 0 | - |
| Inducement expense | 0 | 0 |
| Change in fair value of contingent consideration | 0 | 0 |
| Right of use asset | 0 | 0 |
| Operating lease liability | 0 | 0 |
| Stock-based compensation | 0 | 20,783 |
| Change in fair value of derivative instrument-warrants | -47,275 | 4,102,408 |
| Accounts payable and accrued expenses | -88,093 | -22,693 |
| Prepaid expenses and other assets | -161,911 | -152,433 |
| Asset impairment loss | 0 | 402,746 |
| Net loss | -472,506 | -7,148,459 |
| Net cash used in operating activities | -445,963 | -2,492,782 |
| Investment in related party receivable | 0 | - |
| Investment in license agreement | 0 | 132,117 |
| Net cash used in investing activities | 0 | -132,117 |
| Proceeds from equity and debt issuance under spa, net of discount | 0 | - |
| Proceeds from the issuance of common stock and warrants, net | 0 | 9,000,000 |
| Equity issuance costs | 0 | 802,597 |
| Payments on notes payable | 157,354 | 3,054,517 |
| Net cash provided by financing activities | -157,354 | 5,142,886 |
| Net increase (decrease) in cash | -603,317 | 2,517,987 |
| Cash and cash equivalents at beginning of period | 406,408 | - |
| Cash and cash equivalents at end of period | 2,321,078 | - |
Hepion Pharmaceuticals, Inc. (HEPA)
Hepion Pharmaceuticals, Inc. (HEPA)